Novo Nordisk’s ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
Source
Novo Nordisk’s ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
Source
Traders work on the floor of the New York Stock Exchange (NYSE) in New York, US, on Friday, Feb. 6, 2026. Michael Nagle | Bloomberg | Getty Images U.S. Treasury yields edged higher on Wednesday as investors anticipated the Federal Reserve’s meeting minutes and key inflation data. The 10-year Treasury yield rose more than 1 basis point […]
Read More